EA201992175A1 - Композиции и способы, включающие пробиотические молекулы - Google Patents
Композиции и способы, включающие пробиотические молекулыInfo
- Publication number
- EA201992175A1 EA201992175A1 EA201992175A EA201992175A EA201992175A1 EA 201992175 A1 EA201992175 A1 EA 201992175A1 EA 201992175 A EA201992175 A EA 201992175A EA 201992175 A EA201992175 A EA 201992175A EA 201992175 A1 EA201992175 A1 EA 201992175A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- methods including
- peptides
- infections
- probiotic molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/195—Proteins from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Предложены пептиды, которые получены из пробиотических бактерий, которые могут быть полезны для профилактики и/или лечения энтеральных инфекций или неэнтеральных инфекций у субъекта. Пептиды также могут найти применение для снижения вирулентности энтеральных инфекций или неэнтеральных инфекций у субъекта. Также предложены композиции пептидов и композиции, содержащие фракции культуральной среды пробиотических бактерий.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762472047P | 2017-03-16 | 2017-03-16 | |
PCT/CA2018/050319 WO2018165764A1 (en) | 2017-03-16 | 2018-03-16 | Compositions and methods involving probiotic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992175A1 true EA201992175A1 (ru) | 2020-03-05 |
Family
ID=63522209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992175A EA201992175A1 (ru) | 2017-03-16 | 2018-03-16 | Композиции и способы, включающие пробиотические молекулы |
Country Status (16)
Country | Link |
---|---|
US (2) | US20200016290A1 (ru) |
EP (1) | EP3596103A4 (ru) |
JP (1) | JP7252145B2 (ru) |
KR (1) | KR20190141667A (ru) |
CN (1) | CN110621689B (ru) |
AU (2) | AU2018233588A1 (ru) |
BR (1) | BR112019019255A2 (ru) |
CA (1) | CA3056718A1 (ru) |
CL (1) | CL2019002641A1 (ru) |
EA (1) | EA201992175A1 (ru) |
MA (1) | MA52150A (ru) |
MX (1) | MX2019011060A (ru) |
PE (1) | PE20191785A1 (ru) |
PH (1) | PH12019502341A1 (ru) |
SG (1) | SG11201909602TA (ru) |
WO (1) | WO2018165764A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240046640A (ko) | 2017-03-16 | 2024-04-09 | 마이크로신테시스 인크. | 병원균 병독성을 감소시키는 프로바이오틱 분자 |
KR102135195B1 (ko) * | 2018-10-08 | 2020-07-17 | 아주대학교산학협력단 | 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물 |
JP2022540096A (ja) * | 2019-07-02 | 2022-09-14 | マイクロシンテシス インコーポレイテッド | クオラムセンシング阻害剤及び/又はポストバイオティック代謝産物ならびに関連する方法 |
CN112980712A (zh) * | 2019-12-14 | 2021-06-18 | 山东大学 | 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用 |
CN114591879B (zh) * | 2022-05-11 | 2022-12-06 | 中国农业大学 | 一种抑制幽门螺杆菌的发酵乳杆菌及其应用 |
KR102551065B1 (ko) * | 2022-05-12 | 2023-07-03 | 중앙대학교 산학협력단 | 김치로부터 유래된 LAB(lactic acid bacteria)을 유효성분으로 포함하는 항-바이오필름 조성물 |
WO2024097250A1 (en) * | 2022-10-31 | 2024-05-10 | The Trustees Of Columbia University In The City Of New York | Polymeric carrier for probiotics |
CN117815160B (zh) * | 2023-11-08 | 2024-05-28 | 首都医科大学附属北京潞河医院 | 一种黄芪散饮片的制备及其在治疗慢性肾功能不全中的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0395309B1 (en) * | 1989-04-28 | 1995-12-27 | Takara Shuzo Co. Ltd. | Human calpastatin-like polypeptide |
FR2686085B1 (fr) * | 1992-01-10 | 1995-08-04 | Agronomique Inst Nat Rech | Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations. |
WO1994018832A1 (en) * | 1993-02-26 | 1994-09-01 | Dana-Farber Cancer Institute, Inc. | Cd4 mediated modulation of lipid kinases |
US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US8273710B2 (en) * | 2004-12-23 | 2012-09-25 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting DPP-IV and their use |
CN101351554B (zh) * | 2005-10-04 | 2016-05-18 | 索利金尼克斯公司 | 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽 |
US20090214498A1 (en) * | 2005-11-21 | 2009-08-27 | Teagasc- National Diary Products Research Centre | Antimicrobial peptides and bacterial strains that produce them |
US8431528B2 (en) * | 2008-05-16 | 2013-04-30 | University Of Maryland, Baltimore | Antibacterial Lactobacillus GG peptides and methods of use |
US20110262400A1 (en) * | 2008-06-27 | 2011-10-27 | University Of Guelph | Probiotic bacterial molecules and their use in methods to treat/prevent infection by harmful bacteria and to provide nutritional health |
US8758765B2 (en) * | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
GB201001602D0 (en) * | 2010-02-01 | 2010-03-17 | Cytovation As | Oligopeptidic compounds and uses therof |
WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CN104583229B (zh) * | 2012-08-29 | 2020-06-16 | 新加坡科技研究局 | 肽及其应用 |
US9637523B2 (en) * | 2012-08-31 | 2017-05-02 | Westfaelische Wilhelms-Universitaet Muenster | Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease |
US9539223B2 (en) * | 2013-05-01 | 2017-01-10 | Neoculi Pty Ltd | Methods for treating bacterial infections |
WO2015021530A1 (en) * | 2013-08-12 | 2015-02-19 | Mansel Griffiths | Antiviral methods and compositions comprising probiotic bacterial molecules |
JP6262694B2 (ja) * | 2014-08-18 | 2018-01-17 | 森永乳業株式会社 | プロリルオリゴペプチダーゼ阻害剤 |
JP7236216B2 (ja) * | 2015-04-23 | 2023-03-09 | ナントミクス,エルエルシー | がんのネオエピトープ |
KR20240046640A (ko) * | 2017-03-16 | 2024-04-09 | 마이크로신테시스 인크. | 병원균 병독성을 감소시키는 프로바이오틱 분자 |
-
2018
- 2018-03-16 EA EA201992175A patent/EA201992175A1/ru unknown
- 2018-03-16 US US16/494,421 patent/US20200016290A1/en not_active Abandoned
- 2018-03-16 MX MX2019011060A patent/MX2019011060A/es unknown
- 2018-03-16 WO PCT/CA2018/050319 patent/WO2018165764A1/en unknown
- 2018-03-16 JP JP2019572265A patent/JP7252145B2/ja active Active
- 2018-03-16 KR KR1020197030392A patent/KR20190141667A/ko not_active Application Discontinuation
- 2018-03-16 AU AU2018233588A patent/AU2018233588A1/en not_active Abandoned
- 2018-03-16 PE PE2019001881A patent/PE20191785A1/es unknown
- 2018-03-16 SG SG11201909602T patent/SG11201909602TA/en unknown
- 2018-03-16 EP EP18768492.3A patent/EP3596103A4/en active Pending
- 2018-03-16 MA MA052150A patent/MA52150A/fr unknown
- 2018-03-16 CN CN201880031539.XA patent/CN110621689B/zh active Active
- 2018-03-16 BR BR112019019255A patent/BR112019019255A2/pt unknown
- 2018-03-16 CA CA3056718A patent/CA3056718A1/en active Pending
-
2019
- 2019-09-16 CL CL2019002641A patent/CL2019002641A1/es unknown
- 2019-10-14 PH PH12019502341A patent/PH12019502341A1/en unknown
-
2022
- 2022-04-20 AU AU2022202600A patent/AU2022202600B2/en active Active
-
2023
- 2023-06-02 US US18/327,916 patent/US20240016970A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110621689A (zh) | 2019-12-27 |
PH12019502341A1 (en) | 2020-10-12 |
JP2020510095A (ja) | 2020-04-02 |
US20240016970A1 (en) | 2024-01-18 |
MX2019011060A (es) | 2019-12-09 |
MA52150A (fr) | 2020-01-22 |
CN110621689B (zh) | 2024-04-16 |
JP7252145B2 (ja) | 2023-04-04 |
AU2022202600B2 (en) | 2024-01-04 |
CL2019002641A1 (es) | 2020-05-15 |
US20200016290A1 (en) | 2020-01-16 |
EP3596103A1 (en) | 2020-01-22 |
PE20191785A1 (es) | 2019-12-24 |
AU2018233588A1 (en) | 2019-10-31 |
BR112019019255A2 (pt) | 2020-04-14 |
WO2018165764A1 (en) | 2018-09-20 |
CA3056718A1 (en) | 2018-09-20 |
SG11201909602TA (en) | 2019-11-28 |
AU2022202600A1 (en) | 2022-05-12 |
KR20190141667A (ko) | 2019-12-24 |
EP3596103A4 (en) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201992175A1 (ru) | Композиции и способы, включающие пробиотические молекулы | |
MX2023003461A (es) | Tratamiento de infeccion por clostridium difficile. | |
EA201992176A1 (ru) | Пробиотические молекулы для снижения вирулентности патогена | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201990566A1 (ru) | Композиции, содержащие бактериальные штаммы | |
WO2018229236A3 (en) | COMPOSITIONS COMPRISING BACTERIAL STRAINS | |
EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
MX2016014807A (es) | Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados. | |
EA202090683A2 (ru) | Способы и композиции для лечения рака | |
MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
MX2019000428A (es) | Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. | |
EA201990998A1 (ru) | Фармацевтические составы и способы их получения | |
WO2017123610A3 (en) | Bacteria engineered to detoxify deleterious molecules | |
EA202091308A1 (ru) | Модифицированный вакцинный штамм brucella для лечения бруцеллеза | |
MX2020001632A (es) | Composiciones que comprenden cepas bacterianas. | |
EA201691452A1 (ru) | Композиции для применения в лечении аллергических состояний | |
PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
BR112019004102A2 (pt) | imunoterapia para poliomavírus | |
MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
MX365952B (es) | Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa. | |
MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. |